VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | ZUMA-1: safety and efficacy of axicabtagene in refractory non-Hodgkin lymphoma patients

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the ZUMA-1 study (NCT02348216), investigating the safety and efficacy of axicabtagene ciloleucel, CAR-T cell therapy, in relapsed, aggressive follicular lymphoma and marginal zone lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter